Summary
Bristol-Myers Squibb Company (BMY) announced an addition to its Board of Directors with the election of Dr. Deepak L. Bhatt, effective June 14, 2022. The Board's size has been expanded to eleven members to accommodate this appointment. Dr. Bhatt brings extensive experience in cardiovascular medicine, including over 20 years in acute coronary syndromes, preventive cardiology, and interventional techniques. His background includes significant leadership roles at major medical institutions such as Brigham and Women's Hospital, Harvard Medical School, and the Cleveland Clinic, as well as extensive involvement in cardiovascular clinical trials. This strategic appointment is notable for investors as it brings a highly respected medical expert onto the Board, likely strengthening the company's scientific and technological oversight, particularly in areas relevant to BMY's pharmaceutical focus. Dr. Bhatt's independence has been confirmed, and he will serve on the Science and Technology Committee. His compensation aligns with the company's standard director compensation structure.
Key Highlights
- 1BMY's Board of Directors has appointed Dr. Deepak L. Bhatt, an experienced cardiovascular physician and researcher, as a new member.
- 2The Board size has been increased from ten to eleven directors to accommodate the new appointment.
- 3Dr. Bhatt possesses over 20 years of expertise in critical areas of cardiovascular medicine and has led numerous clinical trials.
- 4He holds prominent academic and clinical positions, including Executive Director of Interventional Cardiovascular programs at Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School.
- 5The Board has determined Dr. Bhatt meets independence requirements under NYSE listing standards.
- 6Dr. Bhatt will serve on the Science and Technology Committee, aligning his expertise with a key board function.
- 7His compensation will follow the standard non-employee director arrangement, including an annual retainer and deferred share units.